ServiceNow Surges Nearly 12% Against the Trend as Morgan Stanley Focuses on AI Application Consumerization Inflection Point
nashnova research
While chip stocks sold off hard, ServiceNow rose nearly 12% in five sessions. Morgan Stanley holds its Overweight rating with a $180 target — Wall Street's focus is shifting from who builds AI to who monetizes it.
Chip stocks cratered — why did this software name rally?
From October 19 to 23, ServiceNow gained 11.97% over five straight up-days; the Philadelphia Semiconductor Index fell 3.21% in the same span.
The starkest contrast came October 22: the SOX index plunged 6.72%, the Nasdaq dropped 2.60%, yet ServiceNow still rose 2.53%.
This means → capital is rotating from AI infrastructure (chips, compute) toward AI applications — the companies turning AI into revenue.
As of October 26, shares closed at $158.18. The stock had already climbed over 70% in three months — earnings now need to clear a much higher expectations bar.
What is Morgan Stanley's bull case?
Morgan Stanley published a pre-earnings preview on October 26, reiterating its Overweight rating and $180 target — roughly 13.8% upside.
The bull case rests on three pillars: steady core-workflow demand + AI product consumption billing ramping up + improving federal procurement.
Channel checks show IT operations, security operations, and customer-service pipelines remain solid; federal business has improved versus 2025, with the public sector accounting for roughly 10% of revenue.
In plain terms = Morgan Stanley sees the legacy business holding firm while the new AI line moves from trial to paid adoption — both trending up at once.
Where is the key inflection point for AI monetization?
Morgan Stanley flags the critical next step: customers shifting from buying AI features to consuming them continuously — topping up Assist Packs (prepaid AI-usage bundles) over time.
In Q2, ServiceNow's AI annual contract value crossed $1 billion; AI agent deployments grew ninefold in nine months.
On October 21, the company announced Arc — a long-running AI agent built with Nvidia — is now generally available, bundled into existing tiers at no extra charge.
This means → Arc's commercial value does not come from a standalone price tag. It comes from driving tier upgrades and follow-on consumption — a "get them using it, then earn from usage" playbook.
What is the one number the market is really betting on?
Morgan Stanley's base-case Q3 forecast is not aggressive: subscription revenue of roughly $3.978 billion, adjusted EPS of $1.02 — both near consensus.
The real swing factor is cRPO — current remaining performance obligations, essentially revenue already contracted but not yet recognized. Company guidance implies roughly 20% growth on a constant-currency basis.
Strip out acquisitions, though, and organic growth drops to about 17%. Morgan Stanley believes investors are pricing in roughly 22% cRPO growth — about two points above guidance.
In plain terms = the market is not betting on this quarter's profit. It is betting on how many new contracts get signed for next year — that number matters more for the stock than earnings do.
How wide is the gap among Wall Street targets — and where is the disagreement?
Bank of America maintained Buy and raised its target from $150 to $180; Citi holds Buy at $170; Piper Sandler holds Overweight at $175.
On the more aggressive end: Cantor Fitzgerald raised its Overweight target to $201 (about 27.1% upside); Bernstein holds Outperform at $266 (about 68.2% upside), premised on renewing customers adopting new-tier bundles and effective price increases.
The most bearish scenario comes from Morgan Stanley's own downside case: $75, implying roughly 52.6% downside — reflecting weaker-than-expected AI market expansion plus valuation multiple compression.
This reflects a deeper consensus: Wall Street agrees not on price, but on the question itself — can AI-agent-driven software demand sustainably convert into paying usage at scale, expanding contracts and stronger free cash flow? That is the core question this quarter's earnings must answer.
市场有风险，内容仅供研究参考，不构成投资建议。